MPS Pharmaa Past Earnings Performance
Past criteria checks 0/6
MPS Pharmaa has been growing earnings at an average annual rate of 10.6%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been declining at an average rate of 55.7% per year.
Key information
10.6%
Earnings growth rate
10.6%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | -55.7% |
Return on equity | -37.2% |
Net Margin | -787.5% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How MPS Pharmaa makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 1 | -9 | 5 | 0 |
30 Sep 23 | 1 | -9 | 5 | 0 |
30 Jun 23 | 1 | -10 | 5 | 0 |
31 Mar 23 | 0 | -11 | 5 | 0 |
31 Dec 22 | 0 | -3 | 5 | 0 |
30 Sep 22 | 0 | -3 | 5 | 0 |
30 Jun 22 | 0 | -1 | 4 | 0 |
31 Mar 22 | 0 | -1 | 4 | 0 |
31 Dec 21 | 3 | -7 | -30 | 0 |
30 Sep 21 | 3 | -42 | 4 | 0 |
30 Jun 21 | 2 | -44 | 39 | 0 |
31 Mar 21 | 0 | -44 | 4 | 0 |
31 Dec 20 | 0 | -46 | 39 | 0 |
30 Sep 20 | 0 | -11 | 4 | 0 |
30 Jun 20 | 0 | -12 | 4 | 0 |
31 Mar 20 | 0 | -12 | 5 | 0 |
31 Dec 19 | 0 | -11 | 5 | 0 |
30 Sep 19 | 0 | -12 | 5 | 0 |
30 Jun 19 | 9 | -12 | 5 | 0 |
31 Mar 19 | 8 | -12 | 5 | 0 |
31 Dec 18 | 9 | -11 | 6 | 0 |
30 Sep 18 | 21 | -11 | 6 | 0 |
30 Jun 18 | 28 | -10 | 6 | 0 |
31 Mar 18 | 41 | -9 | 7 | 0 |
31 Dec 17 | 46 | -34 | 9 | 0 |
30 Sep 17 | 44 | -34 | 9 | 0 |
30 Jun 17 | 37 | -35 | 10 | 0 |
31 Mar 17 | 29 | -74 | 10 | 0 |
31 Dec 16 | 32 | -44 | 9 | 0 |
30 Sep 16 | 3 | -46 | 9 | 0 |
30 Jun 16 | -3 | -47 | 8 | 0 |
31 Mar 16 | 14 | -12 | 10 | 0 |
31 Dec 15 | 19 | -21 | 14 | 0 |
30 Sep 15 | 67 | -17 | 14 | 0 |
30 Jun 15 | 109 | -13 | 10 | 0 |
31 Mar 15 | 122 | -7 | 10 | 0 |
31 Dec 14 | 212 | 3 | 11 | 0 |
30 Sep 14 | 263 | 5 | 11 | 0 |
30 Jun 14 | 253 | 5 | 7 | 0 |
31 Mar 14 | 303 | 5 | 10 | 0 |
31 Dec 13 | 255 | 7 | 10 | 0 |
30 Sep 13 | 257 | 4 | 10 | 0 |
30 Jun 13 | 318 | 5 | 5 | 0 |
Quality Earnings: 531686 is currently unprofitable.
Growing Profit Margin: 531686 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 531686 is unprofitable, but has reduced losses over the past 5 years at a rate of 10.6% per year.
Accelerating Growth: Unable to compare 531686's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 531686 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.3%).
Return on Equity
High ROE: 531686 has a negative Return on Equity (-37.19%), as it is currently unprofitable.